A Combination Study of PF-04449913 (Glasdegib) and Azacitidine In Untreated MDS, AML and CMML Patients

This multi center open label Phase 1b study is designed to evaluate the safety, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of glasdegib (PF-04449913) when combined with azacitidine in patients with previously untreated Higher Risk Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML), or Chronic Myelomonocytic Leukemia (CMML). This clinical study includes two components: (a) a safety lead in cohort (LIC) and (b) an expansion phase with an AML cohort and an MDS cohort.

Additional locations may be listed on ClinicalTrials.gov for NCT02367456.

Trial PhasePhase I

Trial Typetreatment

Lead OrganizationPfizer Inc

• Primary IDB1371012
• Secondary IDsNCI-2015-00462, 2014-001345-24, BRIGHT MDS&AML1012
• ClinicalTrials.gov IDNCT02367456